The Journal of Clinical Psychiatry 2003: Vol 64 Index

29 Pages·2003·11.7 MB·English

The Journal of Clinical Psychiatry
Subject Index to Volume 64: January 2003 Through December 2003
ACADEMIC HIGHLIGHTS Effects of clozapine versus haloperidol on measures Diagnosis and treatment of Alzheimer’s disease
Determining and Achieving Therapeutic Targets of impulsive aggression and suicidality in chronic Grossberg, Suppl 9, 3-6
in Attention-Deficit/Hyperactivity Disorder. schizophrenia patients: an open, nonrandomized, Neuropathologic changes in Alzheimer’s disease
Mar 265-276 6-month study. Spivak, July 755-760 Wenk, Suppl 9, 7-10
New Developments in Antipsychotic Therapy. Hostility during admission interview as a short-term Noncholinergic treatment options for Alzheimer’s
Nov 1379-1390 predictor of aggression in acute psychiatric male disease. Sano, Suppl 9, 23-28
Reducing the Risk for Suicide in Schizophrenia inpatients. Troisi, Dec 1460-1464 Noncholinergic Treatments for Alzheimer’s
and Affective Disorders. Sept 1122-1129 Impulsive aggressive behavior: open-label treatment Disease. Suppl 9, 1-31
Adherence see Compliance with citalopram. Reist, Jan 81-85 Search for better noncholinergic treatment options
Adolescents Management of Aggression Across the Life Cycle for Alzheimer’s disease. Mintzer, Suppl 9,
Childhood stimulant treatment and risk for later Suppl 4, 146 18-22
substance abuse. Fischer, Suppl 11, 19-23 Neuroreceptor mechanisms of aggression and its Amitriptyline
Methylphenidate treatment for attention-deficit/ treatment. Swann, Suppl 4, 26-35 Amitriptyline: dual-action antidepressant 7 [letter]I
hyperactivity disorder in children and Olanzapine for self-injurious, aggressive, and Gillman; Thase reply, Nov 1391-1392
adolescents with velocardiofacial syndrome: an disruptive behaviors in intellectually disabled Analgesics
open-label study. Gothelf, Oct 1163-1169 adults: a retrospective, open-label, naturalistic Analgesic effect of antidepressants [letter]
“Outer-directed irritability”: a distinct mood trial. Janowsky, Oct 1258-1265 Fishbain; Detke reply, Jan 96-97
syndrome in explosive youth with a disruptive Randomized placebo-controlled trial of risperidone Anger
behavior disorder? Donovan, June 698-701 for the treatment of aggression, agitation, and Anger in bipolar depression [letter] Benazzi
Pharmacotherapy for attention-deficit/ psychosis of dementia. Brodaty, Feb 134-143 Koh reply, Apr 480-48 ]
hyperactivity disorder (ADHD) decreases Treating aggression in the psychiatric emergency Anticonvulsants see also specific drugs
the risk for substance abuse: findings from a service. Hughes, Suppl 4, 10-15 Efficacy of newer anticonvulsant medications in
longitudinal follow-up of youths with and Treatment of aggression in children and adolescents bipolar spectrum mood disorders. Evins, Suppl
without ADHD. Biederman, Suppl 11, 3-8 with autism and conduct disorder. McDougle, 8, 9-14
Prolactin levels during long-term risperidone Suppl 4, 16-25 Emerging differential roles of GABAergic and
treatment in children and adolescents. Findling, Alcohol antiglutamatergic agents in bipolar disorders
Nov 1362-1369 Psychometric evaluation of the Alcohol Use Ketter, Suppl 3, 15-20
Psychopathology and age at onset of conduct Disorders Identification Test and short Drug Mechanism of action of newer anticonvulsants
problems in juvenile delinquents. Ruchkin, Abuse Screening Test with psychiatric patients in White, Suppl 8, 5-8
Aug 913-920 India. Carey KB, July 767-774 Newer anticonvulsants: dosing strategies and
Treatment of aggression in children and Two cases of alcohol craving curbed by topiramate cognition in treating patients with mood
adolescents with autism and conduct disorder [letter]. Komanduri, May 612 disorders and epilepsy. Meador, Suppl 8, 30-34
McDougle, Suppl 4, 16-25 Use of antidepressants in alcohol-dependent Antidepressants see also specific drugs
Affective Disorders veterans. Petrakis, Aug 865-870 Analgesic effect of antidepressants [letter]
Ethnicity and diagnosis in patients with affective Algorithms Fishbain; Detke reply, Jan 96-97
disorders. Strakowski, July 747-754 Computer algorithm for calculating the adequacy of Antidepressant-related erectile dysfunction
Reducing the Risk for Suicide in Schizophrenia antidepressant treatment in unipolar and bipolar management via avoidance, switching
and Affective Disorders [ACADEMIC depression. Oquendo, July 825-833 antidepressants, antidotes, and adaptation
HIGHLIGHTS]. Sept 1122-1129 Role of algorithms in the detection and treatment of Labbate, Suppl 10, 11-19
Agitation depression in primary care. Klinkman, Supp! 2, Antidepressants and driver impairment: empirical
Agitation and inpatient suicide [letter]. Sharma V; 19-23 evidence from a standard on-the-road test
Busch reply, Dec 1517-1518 Texas Medication Algorithm Project, phase 3 Ramaekers, Jan 20-29
Intramuscular ziprasidone: moving beyond the (TMAP-3): clinical results for patients with a Are antidepressants carcinogenic? a review of
conventional in the treatment of acute agitation history of mania. Suppes, Apr 370-382 preclinical and clinical studies. Sternbach,
in schizophrenia. Brook, Supp! 19, 13-18 Texas Medication Algorithm Project, phase 3 Oct 1153-1162
Randomized placebo-controlled trial of (TMAP-3): rationale and study design. Rush, Computer algorithm for calculating the adequacy of
risperidone for the treatment of aggression, Apr 357-369 antidepressant treatment in unipolar and bipolar
agitation, and psychosis of dementia. Brodaty, Use of algorithms to treat anxiety in primary care. depression. Oquendo, July 825-833
Feb 134-143 Culpepper, Suppl 2, 30-33 Differences in mechanism of action between
Review of the safety and efficacy of droperidol Using treatment algorithms to bring patients to current and future antidepressants. Stahl, Supp!
for the rapid sedation of severely agitated and remission. Trivedi, Suppl 2, 8-13 13, 13-17
violent patients. Shale, May 500-505 Alzheimer’s Disease Do antidepressants induce rapid cycling ’ a gender-
Treatment of agitation in bipolar disorder across Co-use of donepezil and hypnotics among specific association. Yildiz, July 814-818
the life cycle. Alderfer, Suppl 4, 3-9 Alzheimer’s disease patients living in the Effectiveness of antidepressants: comparative
Aggression community. Stahl, Apr 466-472 remission rates. Thase, Suppl 2, 3-7
Aggression in the elderly. Brodaty, Suppl 4, Current treatments for Alzheimer’s disease: Evaluating antidepressant therapies: remission as
3643 cholinesterase inhibitors. Doody, Supp! 9, 11-17 the optimal outcome. Thase, Supp! 13, 18-25
J Clin Psychiatry 64:12, December 2003 1525
Subject Index: Volume 64
How many subjects with major depressive disorder Conventional antipsychotic prescription in unipolar Switching from depot antipsychotic drugs to
meet eligibility requirements of an depression, |: an audit and recommendations olanzapine in patients with chronic
antidepressant efficacy trial? Keitner, Sept for practice. Wheeler Vega, May 568-574 schizophrenia. Godleski, Feb 1 19-|22
1091-1093 Conventional antipsychotic prescription in unipolar Three case reports of modafinil use in treating
Immediate-release versus controlled-release depression, 2: withdrawing conventional sedation induced by antipsychotic medications
formulations: pharmacokinetics of newer antipsychotics in unipolar, nonpsychotic [letter]. Makela, Apr 485-486
antidepressants in relation to nausea. De Vane, patients. Mortimer, June 668-672 Use of atypical antipsychotics in nursing homes.
Suppl 18, 14-19 Conventional, atypical, and combination Liperoti, Sept 1106-1112
Improving adherence to antidepressants: antipsychotic prescriptions: a 2-year Anxiety
a systematic review of interventions comparison. Tempier, June 673-679 Anxiety disorders in 318 bipolar patients:
Vergouwen, Dec 1415-1420 Cost and outcome implications of using typical and prevalence and impact on illness severity
Improving antidepressant adherence. atypical antipsychotics in ordinary practice in and response to mood stabilizer. Henry, Mar
Nemeroff, Suppl 18, 25-30 Italy. Percudani, Nov 1293-1299 331-335
Interactions of antidepressants with Effectiveness of quetiapine versus conventional Anxiety symptoms and quality of life in middle-
neurotransmitter transporters and receptors and antipsychotics in improving cognitive and aged and older outpatients with schizophrenia
their clinical relevance. Richelson, Suppl 13, functional outcomes in standard treatment and schizoaffective disorder. Wetherell, Dec
5-12 settings. Velligan, May 524-531 1476-1482
Linezolid, a monoamine oxidase inhibiting Efticacy and effectiveness of first- and second- Attending to anxiety disorders in primary care.
antibiotic, and antidepressants [letter]. generation antipsychotics in schizophrenia. Stein, Suppl 15, 35-39
Aga, May 609-610 Jaffe, Suppl 17, 3-6 Establishment of remission criteria for anxiety
Long-term antidepressant efficacy and safety of Efficacy of atypical antipsychotics in bipolar disorders. Doyle, Suppl 15, 40-45
olanzapine/fluoxetine combination: a 76-week disorders. Hirschfeld, Suppl 8, 15-21 Introduction: treating depression and anxiety to
open-label study. Corya, Nov 1349-1356 Ethnic differences in use of antipsychotic remission. Schatzberg, Suppl 15, 3-4
Managing treatment-resistant major depression. medication among Texas medicaid clients with New molecular targets for antianxiety interventions.
Nelson, Suppl 1, 5-12 schizophrenia. Opolka, June 635-639 Gorman, Suppl 3, 28-35
New approaches in managing bipolar depression. Factors influencing compliance in schizophrenia Nonhuman primate studies of fear, anxiety, and
Keck, Suppl 1, 13-18 patients. Fleischhacker, Suppl 16, 10-13 temperament and the role of benzodiazepine
New approaches to managing psychotic How long should patients with psychotic receptors and GABA systems. Kalin, Suppl 3,
depression. Schatzberg, Suppl |, 19-23 depression stay on the antipsychotic 41-4
Possible antidepressant-associated activation of medication? Rothschild, Apr 390-396 Role of GABA in anxiety disorders. Lydiard,
mania and psychosis in the mentally retarded: Integrated analysis of acute treatment-emergent Suppl 3, 21-27
four case reports [letter]. Sahay, Apr 481482 extrapyramidal syndrome in patients with Treatment of anxiety in suicidal patients [letter].
Potential new drug delivery systems for schizophrenia during olanzapine clinical trials: Rich; Fawcett reply, Dec 1518-1519
antidepressants: an overview. Kilts, Suppl 18, comparisons with placebo, haloperidol, Use of algorithms to treat anxiety in primary care.
31-33 risperidone, or clozapine. Carlson, Aug Culpepper. Suppl 2, 30-33
Prevalence of antidepressant-associated erectile 898-906 Anxiolytics
dysfunction. Rosen, Supp! 10, 5—10 New approaches in managing bipolar depression. Anxiolytics: past, present, and future agents.
Sildenafil citrate for the management of Keck, Suppl 1, 13-18 Nemeroff, Suppl 3, 3-6
antidepressant-associated erectile dysfunct? un. New approaches to managing psychotic Emerging differential roles of GABAergic and
Nurnberg, Suppl 10, 20-25 depression. Schatzberg, Suppl 1, 19-23 antiglutamatergic agents in bipolar disorders.
Three case reports of modafinil use in treating New Developments in Antipsychotic Therapy Ketter, Suppl 3, 15-20
sedation induced by antipsychotic medications [AcaDEMIC HIGHLIGHTS]. Nov 1379-1390 New molecular targets for antianxiety interventions.
{letter]. Makela, Apr 485 Nonalcoholic steatohepatitis: a possible side effect Gorman, Supp! 3, 28-35
Use of antidepressants in alcohol-dependent of atypical antipsychotics [letter]. Haberfellner, Aripiprazole
veterans. Petrakis, Aug 865-870 July 851 Aripiprazole for the prevention of relapse in
Use of antidepressants in novel combination Optimizing Pharmacologic Treatment of Psychotic stabilized patients with chronic schizophrenia:
therapies. Shelton, Suppl 2, 14-18 Disorders. Suppl 12, 1-100 a placebo-controlled 26-week study. Pigott,
Weight gain in breastfed infants of mothers taking Overview of partial compliance. Marder, Suppl 16, Sept 1048-1056
antidepressant medications. Hendrick, 3-9 Attention-Deficit/Hyperactivity Disorder
Apr 410-412 Prior antipsychotic prescribing in patients currently Childhood stimulant treatment and risk for later
Antiemetic Drugs receiving clozapine: a case note review. Taylor, substance abuse. Fischer, Suppl 11, 19-23
Ups and downs of novel antiemetic drugs, pt |: Jan 30-34 Comparing the abuse potential of methylphenidate
substance P, 5-HT, and the neuropharmacology Racial differences in use of antipsychotics among versus other stimulants: a review of available
of vomiting [Brainstorms]. Stahl, May patients with bipolar disorder [letter]. Szarek; evidence and relevance to the ADHD patient.
498-499 Fleck reply, May 614-615 Kollins, Suppl 11, 14-18
Ups and downs of novel antiemetic drugs, pt 2: Relapse and rehospitalization: comparing oral Determining and Achieving Therapeutic Targets
an illustration [Brainstorms]. Stahl, June and depot antipsychotics. Schooler, Suppl 16, in Attention-Deficit/Hyperactivity Disorder
626-627 14-17 [AcaDEMIC HIGHLIGHTS]. Mar 265-276
Antipsychotics see also specific drugs Reversal of antipsychotic-associated weight gain. Does stimulant treatment lead to substance use
Chlorpromazine equivalent doses for the newer O'Keefe, Aug 907-912 disorders? Faraone, Suppl 11, 9-13
atypical antipsychotics. Woods, June 663-667 Serum leptin and tr'glyceride levels in patients on Long-Term Safety of Methylphenidate in the
Choice of maintenance medication for treatment with atypical antipsychotics. Atmaca, Treatment of ADHD: Dispelling the Myths
schizophrenia. Davis, Suppl 16, 24-33 May 598-604 and Misconceptions About Stimulant Therapy
Combination therapy: is clinical practice leading Similarities and differeiices among antipsychotics. Abuse. Suppl 11, 1-26
the way? [letter] Welch; Stahl reply, Jan 94-96 Tamminga, Suppi 17, 7-10 Methylphenidate treatment for
Comparison of the effects of different routes of Strategies for improving compliance in treatment attention-deficiV~/hyperactivity disorder
antipsychotic administration on of schizophrenia by using a long-acting in children and adolescents with velocardiofacial
pharmacokinetics and pharmacodynamics. formulation of an antipsychotic: clinical studies. syndrome: an open-label study. Gothelf, Oct
Ereshefsky, Suppl 16, 18-23 Kane, Supp! 16, 34-40 1163-1169
1526 J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Occult mood disorders in 104 consecutively Anger in bipolar depression [letter]. Benazzi; Lithium treatment and suicide risk in major
presenting children referred for the treatment of Koh reply. Apr 480-481 affective disorders: update and new findings
attention-deficit/hyperactivity disorder in a Anxiety disorders in 318 bipolar patients: Baldessarini, Suppi 5, 44-52
community mental health clinic. Dilsaver, prevalence and impact on illness severity Maudsley Bipolar Disorder Project: the effect of
Oct 1170-1176 and response to mood stabilizer. Henry, medication, family history, and duration of
Mar 331-335
Pharmacotherapy for attention-deficit/hyperactivity illness on IQ and memory in bipolar | disorder
disorder (ADHD) decreases the risk for Bipolar disorder and schizophrenia: distinct Donaldson, Jan 86-93
substance abuse: findings from a longitudinal illnesses or a continuum? Moller, Suppl 6, Morbidity in 258 bipolar outpatients followed for
follow-up of youths with and without ADHD. 4397 year with daily prospective ratings on the NIMH
Biederman, Suppl 11, 3-8 Bipolar disorder, obesity, and pharmacotherapy- Life Chart Method. Post, June 680-690
Role of executive function in ADHD. Swanson, associated weight gain. Keck, Dec 1426—1435 New approaches in managing bipolar depression
Suppl 14, 35-39 Bipolar Disorder: Origin, Recognition, and Keck, Suppl i, 13-18
Australia Treatment. Suppl 6, 1-28 Newer anticonvulsants: dosing strategies and
Posttraumatic stress disorder and its impact on the Clozapine in treatment-resistant patients with cognition in treating patients with mood
economic and health costs of motor vehicle schizophrenia, schizoaffective disorder, or disorders and epilepsy. Meador, Suppl 8.
accidents in South Australia. Chan, Feb 175-181 psychotic bipolar disorder: a naturalistic 30-34
Autism 48-month follow-up study. Ciapparelli, Apr Nutritional approach to bipolar disorder [letter
Evidence that eicosapentaenoic acid is effective in 451-458 Simmons; Simpson reply, Mar 338-339
treating autism [letter]. Johnson, July 848-849 Conclusions. Bipolar disorder: origin, recognition, Oxcarbazepine treatment of bipolar disordet
Treatment of aggression in children and adolescents and treatment. Rush, Suppl 6, 28 Ghaemi, Aug 943-945
with autism and conduct disorder. McDougle, Decision tree for the treatment of bipolar disorder Perceptions and impact of bipolar d
Suppl 4, 16-25 Sachs, Suppl 8, 3 50 have we real}l y come? results of f the
Automobile Driving Divalproex monotherapy in the treatment of bipolar Depressive and Manic-Depressive
Antidepressants and driver impairment: empirical offspring with mood and behavioral disorders 2000 survey of individuals with
evidence from a standard on-the-road test and at least mild affective symptoms. Chang Hirschfeld, Feb 161-174
Ramaekers, Jan 20-29 KD, Aug 936-942 Placebo-controlled 18-month trial o
Posttraumatic stress disorder and its impact on the divalproex sodium versus olanzapine in the and lithium maintenance treatment in recently
economic and health costs of motor vehicle treatment of acute mania in bipolar disorder: depressed patients with bipolar I disorder
accidents in South Australia. Chan, Feb 175-181 health-related quality of life and medical cost Calabrese, Sept 1013-1024
Baclofen outcomes. Revicki, Mar 288-294 Prophylactic efficacy of lithium versus
Randomized placebo-controlled trial of baclofen for Drug combinations for mania. Mondimore, Suppl 5, carbamazepine in treatment-naive bipolar
cocaine dependence: preliminary effects for 25 3] patients. Hartong, Feb 144-151
individuals with chronic patterns of cocaine use. Drug interactions of lithium and other antimanic: Psychoeducation efficacy in bipolar disordet
Shoptaw, Dec 1440-1448 mood-stabilizing medications. Dunner, Suppl 5, beyond compliance enhance
Basal Ganglia 38-43 Sept 1101-1105
Possible basal ganglia pathology in children with Economic consequences of not recognizing bipolar Racial differences in use of antipsychotics among
complex symptoms. Yaryura-Tobias, Dec disorder patients: a cross-sectional descriptive patients with bipolar disorder [letter]. Szarek
1495-1501 analysis. Birnbaum HG, Oct 1201-1209 Fleck reply, May 614-615
Behavior Efficacy of atypical antipsychotics in bipolar Rapid and non-rapid cycling bipolar disorder
Double-blind comparison of olanzapine versus disorders. Hirschfeld, Suppl 8, 15-21 a meta-analysis of clinical studies. Kupka
risperidone in the acute treatment of dementia- Efficacy of newer anticonvulsant medications Dec 1483-1494
related behavioral disturbances in extended care in bipolar spectrum mood disorders. Evins, Rationale for using lithium in combination with
facilities. Fontaine, June 726-730 Suppl 8, 9-14 other mood stabilizers in the management of
Evaluating the efficacy of habit reversal: Emerging differential roles of GABAergic and bipolar disorder. Goodwin, Suppl 5, 18
comparison with a placebo control. Twohig, antiglutamatergic agents in bipolar disorders. Relationship between postpartum psychosis
Jan 40-48 Ketter, Suppl 3, 15-20 bipolar disorder: a review. Chaudron, Nov
Impulsive aggressive behavior: open-label Estrogen administration does not reduce the rate of 1284-1292
treatment with citalopram. Reist, Jan 81-85 recurrence of affective psychosis after childbirth. Response, remission, and recovery in bipolar
“Outer-directed irritability”: a distinct mood Kumar, Feb 112-118 disorder: what are the realistic treatment goals?
syndrome in explosive youth with a disruptive Factors associated with suicide attempts in 648 Sachs, Suppl 6, 18-2
behavior disorder? Donovan, June 698-701 patients with bipolar disorder in the Stanley Safety and early efficacy of oral-loaded divalproex
Possible basal ganglia pathology in children with Foundation Bipolar Network. Leverich, versus standard-titration divalproex, lithium,
complex symptoms. Yaryura-Tobias, Dec May 506-515 olanzapine, and placebo in the treatment of
1495-1501 Impact of bipolar disorder on a U.S. community acute mania associated with bipolar disorder
Benzodiazepines sample. Calabrese, Apr 425-432 Hirschfeld, July 841-846
GABA systems, benzodiazepines, and substance Integrated family and individual therapy for Safety of available agents used to treat bipolar
dependence. Malcolm, Suppl 3, 36-40 bipolar disorder: results of a treatment disorder: focus on weight gain. Nemeroff,
Benzodiazepine Receptors development study. Miklowitz, Feb 182-191
Nonhuman primate studies of fear, anxiety, and Introduction. Bipolar disorder: origin, recognition, Screening for bipolar disorder in the community
temperament and the role of benzodiazepine and treatment. Rush, Suppl 6, 3 Hirschfeld, Jan 53-59
receptors and GABA systems. Kalin, Suppl 3, Introduction: Using the newer pharmacotherapeutic Selecting effective long-term treatment for bipolar
4) 44 agents as mood stabilizers in bipolar spectrum patients: monotherapy and combinations
Binge-Eating Disorder disorders. Chengappa, Suppl 8, 34 Grof, Suppl 5, 53-61
Citalopram in the treatment of binge-eating Lamotrigine in patients with bipolar disorder Texas Medication Algorithm Project, phase 3
disorder: a placebo-controlled trial. McElroy, and cocaine dependence. Brown ES, Feb (TMAP-3): clinical results for patients with
July 807-813 197-201 a history of mania. Suppes, Apr 370-382
Bipolar Disorders Lithium combinations in acute and maintenance Texas Medication Algorithm Project, phase 3
Achieving Success in the Management of Bipolar treatment of unipolar and bipolar depression. (TMAP-3): rationale and study design. Rush,
Disorder: Is Lithium Sufficient? Suppl 5, 1-64 Fawcett, Suppl 5, 3229-°3277 Apr 357-369
J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Toward an understanding of bipolar disorder and Gutheil TG, Simon RI: Mastering Forensic Spinelli MG (ed): Infanticide: Psychosocial and
its origin. Rush, Suppl 6, 4-8 Psychiatric Practice: Advanced Strategies Legal Perspectives on Mothers Who Kill. Caruso,
Treatment of agitation in bipolar disorder across for the Expert Witness. Alonso, Aug 973 Sep: 1135-1136
the life cycle. Alderfer, Suppl 4, 3-9 Helzer JE, Hudziak JJ (eds): Defining Stahl SM: Essential Psychopharmacology of
Treatment of bipolar disorder. Moller, Suppl 6, Psychopathology in the 21st Century: Antipsychotics and Mood Stabilizers. Salzman,
9-17 DSM-V and Beyond. Salomon, Nov 1399 Aug 973-974
Underdiagnosis of bipolar II disorders in the Herz MI, Marder SR: Schizophrenia: Stein DJ, Hollander.E (eds): American Psychiatric
community [letter]. Benazzi, Sept 1130-1131 Comprehensive Treatment and Management. Publishing Textbook of Anxiety Disorders.
Using the Newer Pharmacotherapeutic Agents as Siris, Mar 345 Appleton, May 617-618
Mood Stabilizers in Bipolar Spectrum Hodges JR (ed): Early-Onset Dementia: A Theorell T (ed): Everyday Biological Stress
Disorders. Suppl 8, 140 Multidisciplinary Approach. Kirshner, Nov Mechanisms. Straumanis, Mar 344-345
Weight gain in the treatment of mood disorders. 1396 Yehuda R (ed): Treating Trauma Survivors With
Aronne, Suppl 8, 22-29 Hofmann SG, Tompson MC (eds): Treating PTSD. Roback, May 617
Bleeding Chronic and Severe Mental Disorders: A Brain
Critical review of selective serotonin reuptake Handbook of Empirically Supported Brain circuits determine destiny in depression: a
inhibitor—associated bleeding: balancing the Interventions. Ronis, Dec 1524 novel approach to the psychopharmacology of
risk of treating hepatitis C—infected patients. Hollander E: Concise Guide to Anxiety Disorders. wakefulness, fatigue, and executive dysfunction
Weinrieb, Dec 1502-1510 Straumanis, Nov 1396-1397 in major depressive disorder. Stahl, Suppl 14,
Body Dysmorphic Disorder Horowitz MJ: Treatment of Stress Response 6-17
Open-label study of citalopram in body Syndromes. Vaillant, Oct 1272-1273 Enlargement of brain cerebrospinal fluid spaces
dysmorphic disorder. Phillips, June 715-720 Howlin P, Udwin O (eds): Outcomes in as a predictor of poor clinical outcome in
Bone Neurodevelopmental and Genetic Disorders. melancholia. Cardoner, June 691-697
Risperidone, but not olanzapine, decreases bone Matthews, Sept 1136 Long-term follow-up of magnetic resonance-
mineral density in female premenopausal Jacobson SA, Pies RW, Greenblatt DJ: Handbook detectable choline signal changes in the
schizophrenia patients. Becker D, July 761-766 of Geriatric Psychopharmacology. Wahid, hippocampus of patients treated with
Books Reviewed Jan 101 electroconvulsive therapy. Obergriesser, July
Arciniegas DB, Beresford TP: Neuropsychiatry: Kaplan GB, Hammer RP Jr (eds): Brain Circuitry 775-780
An Introductory Approach. Rao, May 616-617 and Signaling in Psychiatry: Basic Science and Brain Imaging
Barlow DH: Anxiety and Its Disorders: The Clinical Implications. Salomon, June 737 Cognitive impairment: assessment with brain
Nature and Treatment of Anxiety and Panic, Kupfer DJ, First MB, Regier DA (eds): A Research magnetic resonance imaging and proton magnetic
2nd ed. Prakash, Mar 345-346 Agenda for DSM-IV. McKinney, Dec 1522 resonance spectroscopy. Weiss, Mar 235-242
Bennett MI: Concise Guide to Managing Lieberman JA, Murray R (eds): Comprehensive Efficacy and safety of bilateral rTMS in medication-
Behavioral Health Care Within a Managed Care of Schizophrenia: A Textbook of Clinical resistant depression [letter]. Cohen, May
Care Environment. Strain, Nov 1398 Management. Herz, Apr 490 613-614
Berrios GE, Hodges JR (eds): Memory Disorders Marangell LB, Martinez JM, Silver JM, Yudofsky Magnetic resonance spectroscopy studies of GABA
in Psychiatric Practice. Miller MG, June SC: Concise Guide to Psychopharmacology. in neuropsychiatric disorders. Chang, Supp! 3,
736-737 Roerig, Nov 1397-1398 7-14
Birren JE, Schaie KW (eds): Handbook of the Martin A, Scahill L, Charney DS, Leckman JF BRAINSTORMS
Psychology of Aging, 5th ed. Casten, Feb 221 (eds): Pediatric Psychopharmacology: Antidepressants and somatic symptoms: therapeutic
Chan CH, Luo JS, Kennedy RS: Concise Guide to Principles and Practice. Sexson, Aug 974 actions are expanding beyond affective spectrum
Computers in Clinical Psychiatry. Kramer, Melmed RN: Mind, Body, and Medicine: An disorders to functional somatic syndromes. Stahl,
Integrative Text. Strauss, Jan 101-102 July 745-746
Committee on Cultural Psychiatry: Cultural Meyers WC: Juvenile Sexual Homicide. Bernet, At long last, long-lasting psychiatric medications:
Assessment in Clinical Psychiatry (GAP Report Apr 487 an overview of controlled-release technologies.
145). Kopelowicz, Mar 344 Mondimore FM: Adolescent Depression: A Guide Stahl, Apr 355-356
Csernansky JG (ed): Schizophrenia: A New Guide for Parents. Slomowitz, July 855 Deconstructing psychiatric disorders, pt 1:
for Clinicians. Lee, Apr 489 Paris J: Personality Disorders Over Time: genotypes, symptom phenotypes, and
Dickey B, Sederer LI (eds): Improving Mental Precursors, Course, and Outcome. Lomax, endophenotypes. Stahl, Sept 982-983
Health Care: Commitment to Quality. Bennett, Oct 1271 Deconstructing psychiatric disorders, pt 2: an
Apr 488-489 Peebles-Kleiger MJ: Beginnings: The Art and emerging, neurobiologically based therapeutic
Ernst M, Rumsey JM (eds): Functional Science of Planning Psychotherapy. Nash, strategy for the modern psychopharmacologist.
Neuroimaging in Child Psychiatry. Mrazek, June 736 Stahl, Oct 1145-1146
Jain 102 Phillips KA (ed): Somatoform and Factitious Here today and not gone tomorrow: the curse of
Gelder M, Mayou R, Cowen P: Shorter Oxford Disorders. Sudak, Jan 99-100 chronic pain and other central sensitization
Textbook of Psychiatry, 4th ed. Gershon, Jan Robinson DJ: Brain Calipers, 2nd ed: Descriptive syndromes. Stahl, Aug 863-864
100-101 Psychopathology and the Psychiatric Mental Neurotransmission of cognition, pt 1. Dopamine is a
Gonzalez FJ (ed): H/V and Depression: Context Status Examination. Crowder, Apr 489-490 hitchhiker in frontal cortex: norepinephrine
and Care (UCSF AIDS Health Project Rogers R: Handbook of Diagnostic and Structured transporters regulate dopamine. Stahl, Jan 4-5
Monograph Series, No. 5). Hargrave, Feb Interviewing. Reus, Apr 488 Neurotransmission of cognition, pt 2. Selective
221-222 Scheiber SC, Kramer TAM, Adamowski SE (eds): NRIs are smart drugs: exploiting regionally
Gotlib IH, Hammen CL (eds): Handbook of Core Competenciefso r Psychiatric Practice: selective actions on both dopamine and
Depression. Schnaas, Dec 1523-1524 What Clinicians Need to Know (A Report oft he norepinephrine to enhance cognition. Stahl, Feb
Griez EJL, Faravelli C, Nutt D, Zohar J (eds): American Board of Psychiatry and Neurology). 110-111
Anxiety Disorders: An Introduction to Clinical Weissman, Sept 1135 Neurotransmission of cognition, pt 3. Mechanism of
Management and Research. Brown LL, Jan Shader RI (ed): Manual of Psychiatric action of selective NRIs: both dopamine and
100 Therapeutics, 3rd ed. Freeman, Oct 1272 norepinephrine increase in prefrontal cortex.
Gualtieri CT: Brain Injury and Mental Simon RI, Shuman DW (eds): Retrospective Stahl, Mar 230-231
Retardation: Psychopharmacology and Assessment of Mental States in Litigation: Symptoms and circuits, pt 1: major depressive
Neuropsychiatry. Benjamin, Dec 1522-1523 Predicting the Past. Regan, Oct 1271-1272 disorder. Stahl, Nov 1282-1283
1528 J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Symptoms and circuits, pt 2: anxiety disorders. “Outer-directed irritability”: a distinct mood Clozapine
Stahl, Dec 1408-1409 syndrome in explosive youth with a disruptive Clozapine and pregnancy [letter]. Mendhekar,
Ups and downs of novel antiemetic drugs, pt 1: behavior disorder? Donovan, June 698-701 July 850
substance P, 5-HT, and the neuropharmacology Pharmacotherapy for attention-deficit/hyperactivity Clozapine and venous thromboembolism: further
of vomiting. Stahl, May 498-499 disorder (ADHD) decreases the risk for evidence [letter]. Selten, May 609
Ups and downs of novel antiemetic drugs, pt 2: substance abuse: findings from a longitudinal Clozapine-induced rabbit syndrome [letter].
an illustration. Stahl, June 626-627 follow-up of youths with and without ADHD. Sethi, Feb 219
Breastfeeding Biederman, Suppl 11, 3-8 Clozapine in treatment-resistant patients with
Pharmacokinetics of sertraline excretion into Physical symptoms of depression: unmet needs in schizophrenia, schizoaffective disorder, or
human breast milk: determinants of infant serum special populations. Stewart, Suppl 7, 12-16 psychotic bipolar disorder: a naturalistic
concentrations. Stowe, Jan 73-80 Possible basal ganglia pathology in children with 48-month follow-up study. Ciapparelli,
Safety of St. John’s Wort (Hypericum perforatum) complex symptoms. Yaryura-Tobias, Dec Apr 451-458
during breastfeeding. Lee A,A ug 966-968 1495-1501 Effects of clozapine versus haloperidol on
Weight gain in breastfed infants of mothers taking Prolactin levels during long-term risperidone measures of impulsive aggression and suicidality
antidepressant medications. Hendrick, Apr treatment in children and adolescents. Findling, in chronic schizophrenia patients: an open,
410412 Nov 1362-1369 nonrandomized, 6-month study. Spivak,
Bulimia Nervosa 3-Year naturalistic study of 53 preschool children July 755-760
Treatment of bulimia nervosa with topiramate in a with pervasive developmental disorders treated Prior antipsychotic prescribing in patients currently
randomized, double-blind, placebo-controlled with risperidone. Masi, Sept 1039-1047 receiving clozapine: a case note review. Taylor,
trial, pt 1: improvement in binge and purge Treatment of aggression in children and adolescents Jan 30-34
measures. Hoopes, Nov 1335-1341 with autism and conduct disorder. McDougle, Six-month review of weight and metabolic
Treatment of bulimia nervosa with topiramate in a Suppl 4, 16-25 parameters in patients receiving clozapine,
randomized, double-blind, placebo-controlled Chinese risperidone, olanzapine, or quetiapine [letter].
trial, pt 2: improvement in psychiatric measures. Double-blind, randomized, group-comparative Kelly DL, Sept 1133-1134
Hedges, Dec 1449-1454 study of the tolerability and efficacy of 6w eeks’ Successful treatment with clozapine at higher
Bupropion treatment with mirtazapine or fluoxetine in doses after clozapine-induced priapism [letter]
Effect of bupropion on sexual dysfunction induced depressed Chinese patients. Hong, Aug 921-926 de Nesnera, Nov 1394-1395
by fluoxetine: a case report of hypersexuality Cholesterol Undiagnosed hyperglycemia in clozapine-treated
[letter]. Chollet, Oct 1268-1269 Increased cholesterol levels during paroxetine patients with schizophrenia. Sernyak, May
They could have named it “bupopion” [letter]. administration in healthy men. Lara, Dec 605-608
Jefferson, July 849-850 1455-1459 Ziprasidone augmentation of clozapine in
Burning Mouth Syndrome Cholinesterase Inhibitors 11 patients [letter]. Kaye, Feb 215-216
Burning mouth syndrome as a side effect of SSRIs Current treatments for Alzheimer’s disease: Cocaine
[letter]. Levenson; Maina reply, Mar 336-338 cholinesterase inhibitors. Doody, Suppl 9, 11-17 Olanzapine for cocaine cravings and relapse
Carbamazepine Cigarette Smoking prevention [letter]. Sattar, Aug 969
Carbamazepine treatment of adverse psychiatric High-frequency repetitive transcranial magnetic Lamotrigine in patients with bipolar disorder and
effects after treatment with the nonsteroidal anti- stimulation decreases cigarette smoking. cocaine dependence. Brown ES, Feb 197-201
inflammatory drug piroxicam [letter]. Eser, July Eichhammer, Aug 951-953 Randomized placebo-controlled trial of baclofen
852-854 Citalopram for cocaine dependence: preliminary effects for
Prophylactic efficacy of lithium versus Citalopram for compulsive shopping disorder: individuals with chronic patterns of cocaine use
carbamazepine in treatment-naive bipolar an open-label study followed by double-blind Shoptaw, Dec 1440-1448
patients. Hartong, Feb 144-151 discontinuation. Koran, July 793-798 Cognition
Carcinogenesis Citalopram in the treatment of binge-eating Cognitive impairment: assessment with brain
Are antidepressants carcinogenic? a review of disorder: a placebo-controlled trial. McElroy, magnetic resonance imaging and proton magnetic
preclinical and clinical studies. Sternbach, July 807-813 resonance spectroscopy. Weiss, Mai 935_94)
Oct 1153-1162 Citalopram treatment of fluoxetine-intolerant Effectiveness of quetiapine versus conventional
Celecoxib depressed patients. Calabrese, May 562-567 antipsychotics in improving cognitive and
Lithium interaction with the cyclooxygenase 2 Combined treatment with methylphenidate and functional outcomes in standard treatment
inhibitors rofecoxib and celecoxib and other citalopram for accelerated response in the settings. Velligan, May 524-531
nonsteroidal anti-inflammatory drugs. Phelan, elderly: an open trial. Lavretsky, Dec 1410-1414 Neurotransmission of cognition, pt |. Dopamine
Nov 1328-133 Effectiveness of citalopram for idiopathic chronic is a hitchhiker in frontal cortex: norepinephrine
Charles Bonnet Syndrome fatigue. Hartz, Aug 927-935 transporters regulate dopamine [BRaINsTORMS]
Charles Bonnet Syndrome with visual Efficacy of citalopram as a monotherapy or as an Stahl, Jan 4-5
hallucinations of childhood experience: adjunctive treatment to estrogen therapy for Neurotransmission of cognition, pt 2. Selective
successful treatment of | patient with perimenopausal and postmenopausal women NRIs are smart drugs: exploiting regionally
risperidone [letter]. Maeda, Sept 1131-1132 with depression and vasomotor symptoms. selective actions on both dopamine and
Children Soares, Apr 473-479 norepinephrine to enhance cognition
Childhood stimulant treatment and risk for later Impulsive aggressive behavior: open-label [Brainstorms]. Stahl, Feb 110-111
substance abuse. Fischer, Suppl 11, 19-23 treatment with citalopram. Reist, Jan 81-85 Neurotransmission of cognition, pt 3. Mechanism
Methylphenidate treatment for Morning light treatment hastens the antidepressant of action of selective NRIs: both dopamine and
attention-deficit/hyperactivity disorder in effect of citalopram: a placebo-controlled trial. norepinephrine increase in prefrontal cortex
children and adolescents with velocardiofacial Benedetti, June 648-653 [Brainstorms]. Stahl, Mar 230-231
syndrome: an open-label study. Gothelf, Open-label study of citalopram in body dysmorphic Ziprasidone and cognition: the evolving story
Oct 1163-1169 disorder. Phillips, June 715-720 Harvey, Suppl 19, 33-39
Occult mood disorders in 104 consecutively Clinical Trials Cognitive Therapy
presenting children referred for the treatment How many subjects with major depressive Lithium carbonate versus cognitive therapy as
of attention-deficit/hyperactivity disorder in a disorder meet eligibility requirements of sequential combination treatment strategies in
community mental health clinic. Dilsaver, Oct an antidepressant efficacy trial? Keitner, partial responders to antidepressant medication
1170-1176 Sept 1091-1093 an exploratory trial. Kennedy, Apr 439-444
J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Cohen-Mansfield Agitation Inventory Controlled-Release Technologies Two cases of quetiapine augmentation for
Reporting changes in scores on the Cohen- At long last, long-lasting psychiatric medications: donepezil-refractory visual hallucinations in
Mansfield Agitation Inventory subscales [letter]. an overview of controlled-release technologies dementia with Lewy bodies [letter]. Terao, Dec
Snowdon; Ballard reply, June 732 [Brainstorms]. Stahl, Apr 355-356 1520-1521
Combination Therapy Immediate-release versus controlled-release Depersonalization Disorder
Combination therapy: is clinical practice leading formulations: pharmacokinetics of newer Feeling unreal: a depersonalization disorder update
the way? [letter] Welch; Stahl reply, Jan 94-96 antidepressants in relation to nausea. DeVane, of 117 cases. Simeon, Sept 990-997
Drug combinations for mania. Mondimore, Suppl Suppl 18, 14-19 Depression
5, 25-31 Corrections Achieving remission and managing relapse in
Drug interactions of lithium and other antimanic/ Oral magnesium ion shortens prolonged QTc depression. Thase, Supp! 18, 3-7
mood-stabilizing medications. Dunner, Suppl 5, interval [letter]. Bachman, June 733-734. Adjunct modafinil for the short-term treatment of
38-43 Correction, Aug 972 fatigue and sleepiness in patients with major
Lithium combinations in acute and maintenance Venlafaxine in treatment-resistant obsessive- depressive disorder: a preliminary double-blind,
treatment of unipolar and bipolar depression. compulsive disorder. Hollander E, May placebo-controlled study. DeBattista, Sept
Fawcett, Suppl 546-550. Correction, Aug 972 1057-1064
Rationale for using lithium in combination with Costs of Medical Care see also Aerobic endurance exercise improves executive
other mood stabilizers in the management of Pharmacoeconomics functions in depressed patients. Kubesch, Sept
bipolar disorder. Goodwin, Suppi 5, 18-24 Comparison of managed care charges among 1005-1012
Selecting effective long-term treatment for bipolar patients treated with selective serotonin reuptake Aging male: androgens, erectile dysfunction, and
patients: monotherapy and combinations. Grof, inhibitors for premenstrual dysphoric disorder. depression. Seidman, Supp! 10, 31-37
Suppl 5, 53-61 Endicott, Dec 1511-1516 Brain circuits determine destiny in depression:
Use of antidepressants in novel combination Cost and outcome implications of using typical and a novel approach to the psychopharmacology of
therapies [commentary]. Shelton, Suppl 2, atypical antipsychotics in ordinary practice in wakefulness, fatigue, and executive dysfunction
14-18 Italy. Percudani, Nov 1293-1299 in major depressive disorder. Stahl, Suppl 14,
Comorbidity Divalproex sodium versus olanzapine in the 6-17
Chronic depression and comorbid personality treatment of acute mania in bipolar disorder: Can long-term treatment with antidepressant drugs
disorders: response to sertraline versus health-related quality of life and medical cost worsen the course of depression? Fava GA, Feb
imipramine. Russell, May 554-561 outcomes. Revicki, Mar 288-294 123-133
Psychiatric comorbidity as a predictor of clinical Economic and human impact of new drugs. Chronic depression and comorbid personality
response to nortriptyline in treatment-resistant Lichtenberg, Suppl 17, 15-18 disorders: response to sertraline versus
major depressive disorder. Papakostas, Nov Economic burden of depression in the United imipramine. Russell, May 554-561
1357-1361 States: how did it change between 1990 and Citalopram treatment of fluoxetine-intolerant
Compliance 2000? Greenberg, Dec 1465-1475 depressed patients. Calabrese, May 562-567
Factors influencing compliance in schizophrenia Economic burden of depression with painful Comparative effects of mirtazapine and fluoxetine
patients. Fleischhacker, Suppl 16, 10-13 symptoms. Greenberg, Suppl 7, 17-23 on sleep physiology measures in patients with
Improving adherence to antidepressants: a Economic consequences of not recognizing bipolar major depression and insomnia. Winokur, Oct
systematic review of interventions. Vergouwen, disorder patients: a cross-sectional descriptive 1224-1229
Dec 1415-1420 analysis. Birnbaum HG, Oct 1201-1209 Computer algorithm for calculating the adequacy
Improving antidepressant adherence. Nemeroff, Limiting access to psychiatric services can increase of antidepressant treatment in unipolar and
Supp! 18, 25-30 total health care costs. Horn, Suppl 17, 23-28 bipolar depression. Oquendo, July 825-833
Overview of partial compliance. Marder, Suppl 16, Posttraumatic stress disorder and its impact on the Conventional antipsychotic prescription in unipolar
3-9 economic and health costs of motor vehicle depression, |: an audit and recommendations
Partial compliance and patient consequences in accidents in South Australia. Chan, Feb for practice. Wheeler Vega, May 568-574
schizophrenia: our patients can do better. Keith, 175-181 Conventional antipsychotic prescription in unipolar
Nov 1308-1315 Risperidone compared with olanzapine in a depression, 2: withdrawing conventional
Strategies for improving compliance in treatment naturalistic clinical study: a cost analysis. antipsychotics in unipolar, nonpsychotic
of schizophrenia by using a long-acting Taylor, May 589-597 patients. Mortimer, June 668-672
formulation of an antipsychotic: clinical studies. Unintended outcomes of medicaid drug cost- Depression-free days as a summary measure of
Kane, Suppl 16, 34-40 containment policies on the chronically mentally the temporal pattern of response and remission
Compulsive Shopping Disorder ill. Soumerai, Suppl 17, 19-22 in the treatment of major depression: a
Citalopram for compulsive shopping disorder: Creatine Kinase comparison of venlafaxine, selective serotonin
an open-label study followed by double-blind Olanzapine elevation of serum creatine kinase reuptake inhibitors, and placebo. Mallick,
discontinuation. Koran, July 793-798 [letter]. Marti-Bonmati, Apr 483-484 Mar 321-330
1-Year naturalistic follow-up of patients with Delirium Depression: links with ischemic heart disease and
compulsive shopping disorder. Aboujaoude, Prospective, open-label, flexible-dose study of erectile dysfunction. Roose, Supp! 10, 26-30
Aug 946-950 quetiapine in the treatment of delirium. Sasaki, Depression with physical symptoms: treating to
Conduct Disorder Nov 1316-1321 remission. Fava, Suppl 7, 24-28
Divalproex sodium for the treatment of conduct Dementia Difficult-to-treat depressions: a primary care
disorder: a randomized controlled clinical trial. Double-blind comparison of olanzapine versus perspective. Manning, Suppl 1, 24-31
Steiner, Oct 1183-1191 risperidone in the acute treatment of dementia- Double-blind, placebo-controlled trial of the safety
Psychopathology and age at onset of conduct related behavioral disturbances in extended care and efficacy of selegiline transdermal system
problems in juvenile delinquents. Ruchkin, facilities. Fontaine, June 726-730 without dietary restrictions in patients with
Aug 913-920 Randomized controlled trial of different models of major depressive disorder. Amsterdam, Feb
Treatment of aggression in children and care for nursing home residents with dementia 208-214
adolescents with autism and conduct disorder. complicated by depression or psychosis. Double-blind, randomized, group-comparative
McDougle, Suppl 4, 16-25 Brodaty, Jan 63-72 study of the tolerability and efficacy of 6 weeks’
Consensus Statements Randomized placebo-controlled trial of risperidone treatment with mirtazapine or fluoxetine in
Optimizing Pharmacologic Treatment of Psychotic for the treatment of aggression, agitation, and depressed Chinese patients. Hong, Aug
Disorders. Suppl 12, 1-100 psychosis of dementia. Brodaty, Feb 134-143 921-926
J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Double-blind, randomized, placebo-controlled trial New Approaches to Managing Difficult-to-Treat Texas Medication Algorithm Project, phase 3
of augmentation with lamotrigine or placebo in Depressions. Supp! 1, 1-34 (TMAP-3): rationale and study design. Rush,
patients concomitantly treated with fluoxetine New approaches to managing difficult-to-treat Apr 357-369
for resistant major depressive episodes. Barbosa, depressions. Thase, Suppl 1, 3-4 Treating Depression and Anxiety to Remission:
Apr 403-407 New approaches to managing psychotic Use of Algorithms. Suppl 2, 1-36
Duloxetine in the long-term treatment of major depression. Schatzberg, Suppl 1, 19-23 Treating Depression: New Choices for a Chronic
depressive disorder. Raskin, Oct 1237-1244 Nortriptyline for treatment-resistant depression. Problem. Suppl 18, 1-36
Early improvement under mirtazapine and Nierenberg, Jan 35-39 Treating depression to remission. Zajecka, Supp!
paroxetine predicts later stable response and Open trial of reboxetine in HIV-seropositive 15, 7-12
remission with high sensitivity in patients with outpatients with major depressive disorder. Treatment of leuprolide-induced depression with
major depression. Szegedi, Apr 413-420 Carvalhal, Apr 421-424 inttamuscular testosterone: a case report [letter]
Economic burden of depression in the United States: Physical Symptoms of Depression and Their Freeman, Mar 341-343
how did it change between 1990 and 2000? Impact on Patients and Society. Suppl 7, 1-31 Treatment strategies for sleep disturbance in
Greenberg, Dec 1465-1475 Physical symptoms of depression as a public patients with depression. Doghramji, Suppl 14,
Economic burden of depression with painful health concern. Sartorius, Suppl 7, 34 24-29
symptoms. Greenberg, Suppl 7, 17-23 Physical symptoms of depression: unmet needs. Dermatology
Efficacy and safety of bilateral rTMS in medication- Greden, Suppl 7, 5-11 How common is obsessive-compulsive disorder in
resistant depression [letter]. Cohen, May 613-614 Physical symptoms of depression: unmet needs in a dermatology outpatient clinic? Fineberg, Feb
Efficacy and tolerability of duloxetine, a novel dual special populations. Stewart, Suppl 7, 12-16 152-155
reuptake inhibitor, in the treatment of major Prevention of relapse and recurrence in Developmental Disorders
depressive disorder. Schatzberg, Suppl 13, depression: the role of long-term 3-Year naturalistic study of 53 preschool children
30-37 pharmacotherapy and psychotherapy. with pervasive developmental disorders treated
Efficacy of citalopram as a monotherapy or as an Nierenberg, Suppl 15, 13-17 with risperidone. Masi, Sept 1039-1047
adjunctive treatment to estrogen therapy for Psychiatric comorbidity as a predictor of clinical Treatment of previously undiagnosed psychiatric
perimenopausal and postmenopausal women response to nortriptyline in treatment-resistant disorders in persons with developmental
with depression and vasomotor symptoms. major depressive disorder. Papakostas, Nov disabilities decreased or eliminated self-injurious
Soares, Apr 473-479 1357-1361 behavior. Tsiouris, Sept 1081-1090
Efficacy of controlled-release paroxetine in the Randomized controlled trial of different models of Diabetes
treatment of late-life depression. Rapaport, care for nursing home residents with dementia Olanzapine/risperidone and diabetes risk [letter]
Sept 1065-1074 complicated by depression or psychosis. Lee; Gianfrancesco reply, July 847-848
Electroconvulsive therapy update: recognizing Brodaty, Jan 63-72 Diet
and treating psychotic depression [editorial]. Relationship of personality disorders to treatment Double-blind, placebo-controlled trial of the safety
Fink, Mar 232-234 outcome in depressed outpatients. Mulder, Mar and efficacy of selegiline transdermal system
Fluoxetine augmentation with olanzapine for 259-264 without dietary resirictions in patients with
treatment of chronic resistant depression in an Remission, residual symptoms, and nonresponse major depressive disorder. Amsterdam, Feb
elderly patient: a case report [letter]. Detweiler, in the usual treatment of major depression in 208-214
July 851-852 managed clinical practice. Cuffel, Apr 397-402 Disability
Gepirone extended-release: new evidence for Residual symptoms in depression: can treatment Sexual satisfaction and risk of disability in older
efficacy in the treatment of major depressive be symptom-specific? Menza, May 516-523 women. Onder, Oct 1177-1182
disorder. Feiger, Mar 243-249 Risperidone augmentation decreases rapid eye Divalproex Sodium
How long should patients with psychotic depression movement sleep and decreases wake in Divalproex monotherapy in the treatment of bipolar
stay on the antipsychotic medication? Rothschild, treatment-resistant depressed patients. offspring with mood and behavioral disorders
Apr 390-396 Sharpley, Feb 192-196 and at least mild affective symptoms. Chang
How many subjects with major depressive disorder Role of algorithms in the detection and treatment KD, Aug 936-942
meet eligibility requirements of an antidepressant of depression in primary care. Klinkman, Divalproex sodium for the treatment of conduct
efficacy trial? Keitner, Sept 1091-1093 Suppl 2, 19-23 disorder: a randomized controlled clinical trial
Introduction: erectile dysfunction and comorbid Role of executive function in late-life depression. Steiner, Oct 1183-1191
depression: prevalence, treatment strategies, and Alexopoulos, Suppl 14, 18-23 Divalproex sodium versus olanzapine in the
associated medical conditions. Nurnberg, Supp! Role of the serotonergic and noradrenergic treatment of acute mania in bipolar disorder
10, 34 neurotransmitter systems in the treatment health-related quality of life and medical cost
Introduction: recent developments in achieving of psychological and physical symptoms outcomes. Revicki, Mar 288-294
depression remission. Schatzberg, Suppl 13, of depression. Fava M, Suppl 13, 26-29 Divalproex versus olanzapine in mania [letter]
Introduction: treating depression and anxiety t Sertraline as monotherapy in the treatment Vieta; Zajecka reply, Oct 1266-1267
remission. Schatzberg, Suppl 15, 3-4 of psychotic and nonpsychotic depression. Safety and early efficacy of oral-loaded divalproex
Lithium carbonate versus cognitive therapy as Simpson, Aug 959-965 versus standard-titration divalproex, lithium,
sequential combination treatment strategies in Sertraline versus imipramine treatment of olanzapine, and placebo in the treatment of acute
partial responders to antidepressant medication: comorbid panic disorder and major depressive mania associated with bipolar disorder
an exploratory trial. Kennedy, Apr 439-444 disorder. Lepola, June 654-662 Hirschfeld, July 841-846
Lithium combinations in acute and maintenance Special issues related to the treatment of Donepezil
treatment of unipolar and bipolar depression. depression in women. Yonkers, Suppl 18, 8-13 Can donepezil be considered a mild antipsychotic
Fawcett, Suppl Suicidal ideation and attempts among psychiatric in dementia treatment? a report of donepezil use
Lithium treatment and suicide risk in major affective patients with major depressive disorder. in 6 patients [letter]. Terao, Nov 1392-1393
disorders: update and new findings. Baldessarini, Sokero, Sept 1094-1100 Co-use of donepezil and hypnotics among
Suppl 5, 44-52 Symptoms and circuits, pt 1: major depressive Alzheimer’s disease patients living in the
Managing treatment-resistant major depression. disorder [Brainstorms]. Stahl, Nov 1282-1283 community. Stahl, Apr 466-472
Nelson, Suppl 1, 5-12 Symptoms of fatigue and cognitive/executive Two cases of quetiapine augmentation for
Negative symptoms in depressed and schizophrenic dysfunction in major depressive disorder before donepezil-refractory visual hallucinations in
patients: how do they differ? Bottlender, Aug and after antidepressant treatment. Fava M, dementia with Lewy bodies [letter]. Terao,
954-958 Suppl 14, 30-34 Dec 1520-1521
J Clin Psychiatry 64:12, December 2003 1531
Subject Index: Volume 64
Dosage Elderly Sildenafil citrate for the management of
Chlorpromazine equivalent doses for the newer Aggression in the elderly. Brodaty, Suppl 4, 36-43 antidepressant-associated erectile dysfunction.
atypical antipsychotics. Woods, June 663-667 Anxiety symptoms and quality of life in middle- Nurnberg, Suppl 10, 20-25
Newer anticonvulsants: dosing strategies and aged and older outpatients with schizophrenia Escitalopram
cognition in treating patients with mood and schizoaffective disorder. Wetherell, Dec Escitalopram in the treatment of panic disorder:
disorders and epilepsy. Meador, Suppl 8, 30-34 1476-1482 a randomized, double-blind, placebo-controlled
Droperidol Combined treatment with methylphenidate and trial. Stahl, Nov 1322-1327
Review of the safety and efficacy of droperidol for citalopram for accelerated response in the Estrogen
the rapid sedation of severely agitated and elderly: an open trial. Lavretsky, Dec 1410-1414 Efficacy of citalopram as a monotherapy or as an
violent patients. Shale, May 500-505 Efficacy of controlled-release paroxetine in the adjunctive treatment to estrogen therapy for
Drug Abuse treatment of late-life depression. Rapaport, Sept perimenopausal and postmenopausal women
Psychometric evaluation of the Alcohol Use 1065-1074 with depression and vasomotor symptoms.
Disorders Identification Test and short Drug Fluoxetine augmentation with olanzapine for Soares, Apr 473-479
Abuse Screening Test with psychiatric patients treatment of chronic resistant depression in an Estrogen administration does not reduce the rate
in India. Carey KB, July 767-774 elderly patient: a case report [letter]. Detweiler, of recurrence of affective psychosis after
Drug Administration July 851-852 childbirth. Kumar, Feb 112-118
Can long-term treatment with antidepressant drugs Physical symptoms of depression: unmet needs in Ethnicity
worsen the course of depression? Fava GM, Feb special populations. Stewart, Suppl 7, 12-16 Ethnic differences in use of antipsychotic
123-133 Probing the safety of medications in the frail medication among Texas medicaid clients with
Comparison of the effects of different routes of elderly: evidence from a randomized clinical schizophrenia. Opolka, June 635-639
antipsychotic administration on trial of sertraline and venlafaxine in depressed Ethnicity and diagnosis in patients with affective
pharmacokinetics and pharmacodynamics. nursing home residents. Oslin, Aug 875-882 disorders. Strakowski, July 747-754
Ereshefsky, Suppl 16, 18-23 Role of executive function in late-life depression. Executive Dysfunction
Double-blind, placebo-controlled trial of the safety Alexopoulos, Suppl 14, 18-23 Brain circuits determine destiny in depression: a
and efficacy of selegiline transdermal system Sexual satisfaction and risk of disability in older novel approach to the psychopharmacology of
without dietary restrictions in patients with women. Onder, Oct 1177-1182 wakefulness, fatigue, and executive dysfunction
major depressive disorder. Amsterdam, Feb Treatment of agitation in bipolar disorder across the in major depressive disorder. Stahl, Suppl 14,
208-214 life cycle. Alderfer, Suppl 4, 3-9 6-17
Immediate-release versus conirolled-release Use of atypical antipsychotics in nursing homes. Differential diagnosis of fatigue and executive
formulations: pharmacokinetics of newet Liperoti, Sept 1106-1112 dysfunction in primary care. Lieberman,
antidepressants in relation to nausea. De Vane, Electroconvulsive Therapy Suppl 14, 40-43
Supp! '8, 14-19 Dilemma of unmodified electroconvulsive therapy Fatigue and executive dysfunction in the primary
Intramuscular ziprasidone: moving beyond the [commentary]. Andrade, Oct 1147-1152 care setting [Primary Care commentary].
conventional in the treatment of acute agitation Electroconvulsive therapy update: recognizing and Culpepper, Suppl 14, 5
in schizophrenia. Brook, Supp! 19, 13-18 treating psychotic depression [editorial]. Fink, Introduction: optimizing wakefulness in patients
Potential new drug delivery systems for Mar 232-234 with fatigue and executive dysfunction. Stahl,
antidepressants: an overview. Kilts, Suppl 18, -ong-term follow-up of magnetic resonance- Suppl 14, 3-4
31-33 detectable choline signal changes in the Role of executive function in ADHD. Swanson,
Relapse and rehospitalization: comparing oral and hippocampus vf patients treated with Suppl 14, 35-39
depot antipsychotics. Schooler, Suppl 16, 14-17 electroconvulsive therapy. Obergriesser, Role of executive function in late-life depression.
Strategies for improving compliance in treatment of July 775-780 Alexopoulos, Suppl 14, 18-23
schizophrenia by using a long-acting Pretreatment with ibuprofen to prevent Symptoms of fatigue and cognitive/executive
formulation of an antipsychotic: clinical studies. electroconvulsive therapy—induced headache. dysfunction in major depressive disorder before
Kane, Suppl 16, 34-40 Leung, May 551-553 and after antidepressant treatment. Fava M,
Treatment of schizophrenia with long-acting E-mail Suppl 14, 30-34
injectable risperidone: 2 !2-month open-label Suggested guidelines for e-mail communication in Exercise
trial of the first long-acting second psychiatric practice. Silk, July 799-806 Aerobic endurance exercise improves executive
antipsychotic. FPleiseunacher, Oct 12 Epilepsy ; functions in depressed patients. Kubesch,
Duloxetine Case report of hypomania following vagus nerve Sept 1005-1012
Duloxetine in 2-term treatmeny of major stimulation for refractory epilepsy [letter]. Klein, Expert Consensus Guideline Series
askin, Oct 1237--1244 Apr 435 Optimizing Pharmacologic Treatment of Psychotic
Newer anticonvulsants: dosing strategies and Disorders. Supp! 12, 1-100
ty of dulox etine, a no el dval
nent of major COgMiuon in treatins mood Extrapyramidal Syndrome
Suppl 13. disorders and epilepsy. Meador uppl 8, 30-34 integrated analysis of acute treatment-emergent
Erectile Dysfunction extrapyramidal syndrome in patients with
m about the rmplied role ior Aging maie: androgens, erectile dysfunction schizophrenia during olanzapine clinical trials:
in pain management {let anid Cepression. Seidman, Suppi 10, 31-37 comparisons with placebo, haloperidol,
Anitidenressant-related erectiie dysiuaction risperidone, or clozapine. Carlson,
Lconomics see Costs of Medici Caz managemei lance, switching Aug 898-906
ems antidepressants, ait family Therapy
Janzapiic-oas ssociaied bilatere Lubbate, Supp! {*! Integrated family and individual therapy for
[letter]. Christensen, Aug 2ssi0n: links wil se and bipolar disorder: results of a treatment
Education ile Gystunct ), 25-30 dev2lopment study. Miklowitz, Feb 182-191
Peychoeducation cfficacy in bipolar Fatigue
beyond compliance enhancement Adjunct modafinil for the short-term treatment of
Sept 1104-1105 | conditions. Nurnberg, fatigue and sleepiness in patients with major
cosapeni:e oie Actd inp! | depressive disorder: a preliminary double-blind,
Evidence that cosapentaenoic acid is effective in Prevalence oO: antici ressant-associatsd erectile placevo-controlled study. DeBattista, Sept
treating autism {letter}. Johnson, July $48-849 dysfunctioi. 2osen, Su 5-10 1657—, 064
J Clin Psychiatry 64:12, December 2003
Subject Index: Volume 64
Brain circuits determine destiny in depression: a New molecular targets for antianxiety interventions. Heart Disease
novel approach to the psychopharmacology of Gorman, Suppl 3, 28-35 Depression: links with ischemic heart disease and
wakefulness, fatigue, and executive dysfunction Nonhuman primate studies of fear, anxiety, and erectile dysfunction. Roose, Suppl 10, 26-30
in major depressive disorder. Stahl, Suppl 14, temperament and the role of benzodiazepine Hepatitis
6-17 receptors and GABA systems. Kalin, Suppl 3, Critical review of selective serotonin reuptake
Differential diagnosis of fatigue and executive 4144 inhibitor—associated bleeding: balancing the
dysfunction in primary care. Lieberman, Supp! Role of GABA in anxiety disorders. Lydiard, risk of treating hepatitis C-infected patients
14, 40-43 Suppl 3, 21-27 Weinrieb, Dec 1502-1510
Effectiveness of citalopram for idiopathic chronic Role of GABA in neuropsychiatric disorders: Prevalence of hepatitis A, hepatitis B, and HIV
fatigue. Hartz, Aug 927-935 a review of GABA agents. Suppl 3, 1-47 among hepatitis C—seropositive state hospital
Fatigue and executive dysfunction in the primary Gender patients: results from Oregon State Hospital.
care setting [Primary Care commentary]. Do antidepressants induce rapid cycling? a gender- Meyer, May 540-545
Culpepper, Suppl 14, 5 specific association. Yildiz, July 814-818 Psychiatric symptoms in patients with chronic
Introduction: optimizing wakefulness in patients Gender differences in pathological gambling. hepatitis C receiving interferon alfa-2b therapy
with fatigue and executive dysfunction. Stahl, Ibanez, Mar 295-301 Kraus, June 708-714
Suppl 14, 3-4 Generalized Anxiety Disorder Herbal Preparations
Symptoms of fatigue and cognitive/executive Efficacy and tolerability of paroxetine for the long- Acute liver failure after administration of the herbal
dysfunction in major depressive disorder before term treatment of generalized anxiety disorder. tranquilizer kava-kava (Piper methysticum)
and after antidepressant treatment. Fava M, Stocchi, Mar 250-258 [letter]. Brauer, Feb 216-218
Sup14p, 3l0- 34 Hydroxyzine for generalized anxiety disorder HIV
Fluoxetine [letter]. Sagduyu, Mar 343 Open trial of reboxetine in HIV-seropositive
Citalopram treatment of fluoxetine-intolerant Randomized, double-blind, placebo-controlled outpatients with major depressive disorder
depressed patients. Calabrese, May 562-567 study of classical homeopathy in generalized Carvalhal, Apr 421424
Comparative effects of mirtazapine and fluoxetine anxiety disorder. Bonne, Mar 282-287 Prevalence of hepatitis A, hepatitis B, and HIV
on sleep physiology measures in patients with Tiagabine for the treatment of generalized anxiety among hepatitis C—seropositive state hospital
major depression and insomnia. Winokur, Oct disorder: a randomized, open-label, clinical trial patients: results from Oregon State Hospital.
1224-1229 with paroxetine as a positive control. Rosenthal, Meyer, May 540-545
Double-blind, randomized, group-comparative Oct 1245-1249 Homeopathy
study of the tolerability and efficacy of 6 weeks’ Treating generalized anxiety disorder. Gorman, Randomized, double-blind, placebo-controlled
treatment with mirtazapine or fluoxetine in Supp! 2, 24-29 study of classical homeopathy in generalized
depressed Chinese patients. Hong, Aug 921-92¢ Genetics anxiety disorder. Bonne, Mar 282-287
Double-blind, randomized, placebo-controlled trial Deconstructing psychiatric disorders, pt 1: Hormones
of augmentation with lamotrigine or placebo in genotypes, symptom phenotypes, and Aging male: androgens, erectile dysfunction,
patients concomitantly treated with fluoxetine endophenotypes [Brainstorms]. Stahl, and depression. Seidman, Suppl 10, 31-37
for resistant major depressive episodes. Barbosa, Sept 982-983 Human Immunodeficiency Virus see HIV
Apr 403-407 Gepirone Hydroxyzine
Effect of bupropion on sexual dysfunction induced Gepirone extended-release: new evidence for Hydroxyzine for generalized anxiety disorder
by fluoxetine: a case report of hypersexuality efficacy in the treatment of major depressive letter]. Sagduyu, Mar 343
[letter]. Chollet, Oct 1268-1269 disorder. Feiger, Mar 243-249 Hyperglycemia
Fluoxetine augmentation with olanzapine for Geriatric Psychiatry see Elderly Undiagnosed hyperglycemia in clozapine-treated
treatment of chronic resistant depression in an Government patients with schizophrenia. Sernyak, May
elderly patient: a case report [letter]. Detweiler, Government perspective [commentary]. Parks, 605-608
July 851-852 Suppl 17, 37-38 Hypnotics
Long-term antidepressant efficacy and safety of Gynecomastia Co-use of donepezil and hypnotics among
olanzapine/fluoxetine combination: a 76-week Case of gynecomastia during paroxetine therapy Alzheimer’s disease patients living in the
open-label study. Corya, Nov 1349-1356 {letter}. Damsa, Aug 971 community. Stahl, Apr 466-472
Fluvoxamine Habit Reversal Hypomania
Double-blind, placebo-controlled study of the Evaluating the efficacy of habit reversal: Case report of hypomania following vagus nerve
efficacy and safety of controlled-release comparison with a placebo control. Twohig, stimulation for refractory epilepsy [letter]
fluvoxamine in patients with obsessive- Jan 40-48 Klein, Apr 485-486
compulsive disorder. Hollander E, June Hair Pulling see Trichotillomania Ibuprofen
640-647 Hallucinations Pretreatment with ibuprofen to prevent
Formularies Two cases of quetiapine augmentation for electroconvulsive therapy—induced headache
Case for Physician Choice: Implications for donepezil-refractory visual hallucinations in Leung, May 551-553
Restricted Formularies. Suppl 17, 140 dementia with Lewy bodies [letter]. Terao, Imipramine
Impact of formularies on clinical innovation. Dec 1520-1521 Chronic depression and comorbid personality
Goodwin, Suppl 17, 11-14 Haloperidol disorders: response to sertraline versus
Weighing the evidence: trends in managed care Effects of clozapine versus haloperidol on measures imipramine. Russell, May 554-561
formulary decision making. de Lissovoy, of impulsive aggression and suicidality in Sertraline versus imipramine treatment of comorbid
Suppl 17, 29-32 chronic schizophrenia patients: an open, panic disorder and major depressive disorder
Fosphenytoin nonrandomized, 6-month study. Spivak, Lepola, June 654-662
Intravenous fosphenytoin in acute mania. July 755-760 impulsivity
Applebaum, Apr 408-409 Incidence of tardive dyskinesia in first-episode Impulsive aggressive behavior: open-label
Gamma-Aminobutyric Acid psychosis patients treated with low-dose treatment with citalopram. Reist, Jan
GABA systems, benzodiazepines, and substance haloperidol. Oosthuizen, Sept 1075-1080 81-85
dependence. Malcolm, Suppl 3, 36-40 Headache Incontinence
Magnetic resonance spectroscopy studies of GABA Pretreatment with ibuprofen to prevent Case report of olanzapine-induced fecal
in neuropsychiatric disorders. Chang, Suppl 3, electroconvulsive therapy—induced headache. incontinence [letter]. Mendhekar,
7-14 Leung, May 551-553 Mar 339
J Clin Psychiatry 64:12, December 2003
India hormone: a systematic review. Briken, Aug intravenous fosphenytoin in acute mania.
Psychometric tioOfn t ix 8Y0-897 Applebaum \pr 4 R409
Disorders IdentificationT s TL eavyevetriinr ace>r amy y thtiheo treatment of acute mania:
\buse Screening ipolar Outpatients followed foi pen add-on study with an on-off-on design.
in India. Carey K nective ratings cn the NIMH 781-784
Infants Lite Char ine 680-690 Mania associated with initiation of ziprasidone
Pharmacokinetics of sertraline excretion init Light Thera ovotherapy jletter|. Nolan, Mar 336
human breast milk: determinants of infant Linezolid Mania irom dose-related ziprasidone
serum concemrations. Stowe, Jan 73-80 Linezolid, a monoamine oxidase inhibiting antibiotic, augmentation of an SSRI [letter]. Privitera,
Weight gain in breastfed infants of mothers and antidepressants [letter]. Aga, May 609-610 Nov 1393-1394
taking antidepressant medications. Hendrick Lipids 1-Year follow-up of patients treated with
Apr 410-412 Effects of mirtazapine on plasma lipid profiles in risperidone and topiramate for a manic episode.
Insomnia healthy subjects. Nicholas, Aug 883-889 Vieta, July 834-839
Comparative effects of mirtazapine and fluoxetine Lithium Maudsley Bipolar Disorder Project
on sicep physiol gy Measures in patients with Drug interactions of lithium and other antimanic; Maudsley Bipolar Disorder Project: the effect of
major depression and insomnia. Winokur, Oct mood-stabilizing medications. Dunner, Suppl 5, medication, family history, and duration of
1224-1229 38-43 illness on IQ and memory in bipolar I disorder.
Insulin Lithium carbonate versus cognitive therapy as Donaldson, Jan 86-93
Olanzapine induces insulin resistance: results sequential combination treatment strategies in Medicaid
from a prospective study. Ebenbichler, Dec partial responders to antidepressant medication: Unintended outcomes of medicaid drug cost-
1436-1439 an exploratory trial. Kennedy, Apr 439-444 containment policies on the chronically
Intelligence Lithium combinations in acute and maintenance mentally ill. Soumserai, Supp! 17, 19-22
Maudsley Bipolar Disorder Project: the effect oi treatment of unipolar and bipolar depression. Melancholia
medication, family history, and duration of Fawcett, Suppl 5, 32-37 Enlargement of brain cerebrospinal fluid spaces
illness on IQ and memory in bipolar I disorder. hium interaction with the cyclooxygenase 2 as a predictor of poor clinical outcome in
Donaldson, Jan 86-93 inhibitors rofecoxib and celecoxib and other melancholia. Cardoner, June 691-697
Interferon nonsteroidal anti-inflammatory drugs. Phelan, Memory
Psychiatric symptoms in patients with chronic Nov 1328-133 Maudsley Bipolar Disorder Project: the effect of
hepatitis C receiving interferon alfa-2b therapy. Lithium treatment and suicide risk in major affective medication, family history, and duration of
Kraus, June 708-714 disorders: update and new findings. Baldessarini, illness on IQ and memory in bipolar I disorder.
Internet Suppl 5, 44-52 Donaldson, Jan 86-93
Internet pharmacy prescription and phentermine Placebo-controlled 18-month trial of lamotrigine Men
overdose [letter]. Takeshita, Feb 215 and lithium maintenance treatment in recently Hostility during admission interview as a short-
Italy depressed patients with bipolar I disorder. term predictor of aggression in acute
Cost and outcome implications of using typical and Calabrese, Sept 1013-1024 psychiatric male inpatients. Troisi, Dec
atypical antipsychotics in ordinary practice in Prophylactic efficacy of lithium versus 1460-1464
Italy. Percudani, Nov 1293-1299 carbamazepine in treatment-naive bipolar patients Increased cholesterol levels during paroxetine
Journal of Clinical Psychiatry Hartong, Feb 144-15] administrati’ a in healthy men. Lara, Dec
On-line manuscript submission and peer review. Rationale for using lithium in combination with other 1455-1459
Jan 6-7 mood stabilizers in the management of bipolar Past anabolic-androgenic steroid use among men
Happy New Year! [editorial] Gelenberg, Jan 8-1 | disorder. Goodwin, Suppl 5, 18-24 admitted for substance abuse treatment: an
Kava-Kava Safety and early efficacy of oral-loaded divalproex underrecognized problem? Kanayama, Feb
Acute liver failure after administration of the herbal versus standard-titration divalproex, lithium, 156-160
tranquilizer Kava-Kava (Piper methysticum) olanzapine, and placebo in the treatment of acute Mental Retardation
[letter]. Brauer, Feb 216-218 mania associated with bipolar disorder. Possible antidepressant-associated activation of
Lamotrigine Hirschfeld, July 841-846 mania and psychosis in the mentally retarded:
Double-blind, randomized, placebo-controlled trial Use of mood stabilizers as plasticity enhancers in the four case reports [letter]. Sahay, Apr 481-482
of augmentation with lamotrigine or placebo in treatment of neuropsychiatric disorders. Gray, Weight, lipids, glucose, and behavioral measures
patients concomitantly treated with fluoxetine for Suppl! 5, 3-17 with ziprasidone treatment in a population with
resistant major depressive episodes. Barbosa, Liver Failure mental retardation. Cohen, Jan 60-62
Apr 403-407 Acute liver failure after administration of the herbal Metabolic Syndrome
Lamotrigine in patients with bipolar disorder tranquilizer kava-kava (Piper methysticum). Metabolic syndrome in patients with
and cocaine dependence. Brown ES, Feb Brauer, Feb 216-218 schizophrenia. Heiskanen, May 575-579
197-201 Magnesium Metabolism
Placebo-controlled 18-month trial of lamotrigine Oral magnesium ion shortens prolonged QTc Olanzapine elevation of serum creatine kinase
and lithium maintenance treatment in recently interval. Bachman, June 733-734. Correction, {letter]. Marti-Bonmati, Apr 483-484
depressed patients with bipolar I disorder. Aug 972 Olanzapine induces insulin resistance: results from
Calabrese, Sept 1013-1024 Magnetic Resonance Imaging see Brain Imaging a prospective study. Ebenbichler, Dec
Leuprolide Managed Care 1436-1439
Treatment of leuprolide-induced depression with Health care organization perspective [commentary]. Serum leptin and triglyceride levels in patients on
intramuscular testosterone: a case report [letter]. Goldman, Suppl 17, 35-36 treatment with atypical antipsychotics. Atmaca,
Freeman, Mar 341-343 Weighing the evidence: trends in managed care May 598-604
Levetiracetam formulary decision making. de Lissovoy, Suppl Six-month review of weight and metabolic
Levetiracetam in the treatment of acute mania: 17, 29-32 parameters in patients receiving clozapine,
an open add-on study with an on-off-on design. Mania risperidone, olanzapine, or quetiapine [letter].
Grunze, July 781-784 Divalproex versus olanzapine in mania [letter]. Vieta; Kelly DL, Sept 1133-1134
LHRH Agonists Zajecka reply, Oct 1266-1267 Weight, lipids, glucose, and behavioral measures
Pharmacotherapy of paraphilias with long-acting Drug combinations for mania. Mondimore, Suppl 5, with ziprasidone treatment in a population with
agonists of luteinizing hormone-releasing 25-31 mental retardation. Cohen, Jan 60-62
1534 J Clin Psychiatry 64:12, December 2003